Merck's Challenge to Medicare Drug Price Negotiations Fails Again

A federal judge has rejected Merck & Co.'s attempt to overturn Medicare's drug price negotiations, ruling in favor of the program after three years of litigation. The decision was made by Judge Colleen Kollar-Kotelly of the US District Court for the District of Columbia.

The court found that there is no genuine dispute over any material facts and that Merck has the ability to withdraw from the program and sell its selected drug at its own desired price on the private market. This ruling aligns with previous decisions made by other courts dealing with similar challenges to the program.